On March 13, 2019 Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene therapies for rare diseases, reported that Manuel Litchman, M.D., President and Chief Executive Officer, will present a company overview at Oppenheimer’s 29th Annual Healthcare Conference (Press release, Mustang Bio, MAR 13, 2019, View Source [SID1234534317]). The presentation will take place on Tuesday, March 19, 2019, at 4:30 p.m. EDT at the Westin New York Grand Central in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!